Advertisement

Topics

Targacept, Inc. Company Profile

08:32 EDT 21st March 2019 | BioPortfolio

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s lead program, TC-5214, is in Phase 3 development as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline, and uses its expertise to create significant alliances with global pharmaceutical companies. Targacept is committed to Building Health and Restoring Independence™ for patients. For more information, please visit www.targacept.com.


News Articles [1 Associated News Articles listed on BioPortfolio]

PTV News: Dec 3, 2009

Top stories on December 3rd, 2009: AZ in billion dollar deal for Targacept's antidepressant Roche's diabetes drug "better than Merck's Januvia" Dyax shares skyrocket on FDA approval of Kalbitor ...

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers

Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression a...

An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with DS...

Companies [4 Associated Companies listed on BioPortfolio]

Targacept, Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively m...

Targacept

Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targ...

Targacept Inc.

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively m...

Targacept, Inc. and Catalyst Biosciences, Inc.

More Information about "Targacept, Inc." on BioPortfolio

We have published hundreds of Targacept, Inc. news stories on BioPortfolio along with dozens of Targacept, Inc. Clinical Trials and PubMed Articles about Targacept, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Targacept, Inc. Companies in our database. You can also find out about relevant Targacept, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record